p18SMI-22 is a novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein. References: Ardenne M, Reitnauer PG. [Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic possibilities]. Arzneimittelforschung. 1975 Sep;25(9):1369-79. German. PubMed PMID: 22.

纯度：≥98%

CAS：1043924-66-8